NasdaqGS - Delayed Quote • USD
Arbutus Biopharma Corporation (ABUS)
At close: 4:00 PM EDT
After hours: 4:05 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 5 | 3 |
| Avg. Estimate | -0.11 | -0.11 | -0.45 | -0.53 |
| Low Estimate | -0.13 | -0.14 | -0.6 | -0.68 |
| High Estimate | -0.1 | -0.09 | -0.38 | -0.43 |
| Year Ago EPS | -0.1 | -0.1 | -0.44 | -0.45 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 3 |
| Avg. Estimate | 2.15M | 2.17M | 7.76M | 10.02M |
| Low Estimate | 2.1M | 2.1M | 4.6M | 8.6M |
| High Estimate | 2.21M | 2.28M | 9.27M | 10.88M |
| Year Ago Sales | 6.69M | 4.65M | 18.14M | 7.76M |
| Sales Growth (year/est) | -67.80% | -53.30% | -57.20% | 29.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.14 | -0.11 | -0.11 | -0.12 |
| EPS Actual | -0.1 | -0.1 | -0.12 | -0.12 |
| Difference | 0.04 | 0.01 | -0.01 | 0 |
| Surprise % | 28.60% | 9.10% | -9.10% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.11 | -0.11 | -0.45 | -0.53 |
| 7 Days Ago | -0.11 | -0.11 | -0.45 | -0.53 |
| 30 Days Ago | -0.11 | -0.11 | -0.45 | -0.53 |
| 60 Days Ago | -0.1 | -0.1 | -0.43 | -0.38 |
| 90 Days Ago | -0.1 | -0.1 | -0.43 | -0.38 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ABUS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -10.00% | -- | -- | 1.60% |
| Next Qtr. | -10.00% | -- | -- | 10.50% |
| Current Year | -2.30% | -- | -- | 5.20% |
| Next Year | -17.80% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 4/4/2024 |
| Reiterates | Chardan Capital: Buy to Buy | 3/1/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/1/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/12/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/4/2023 |
| Reiterates | Chardan Capital: Buy to Buy | 8/4/2023 |
Related Tickers
ROIV Roivant Sciences Ltd.
10.46
+0.97%
ARWR Arrowhead Pharmaceuticals, Inc.
22.33
-1.24%
GRTS Gritstone bio, Inc.
0.7366
-0.95%
ALNY Alnylam Pharmaceuticals, Inc.
144.41
-0.52%
IMVT Immunovant, Inc.
28.22
-0.35%
RGLS Regulus Therapeutics Inc.
2.1300
-4.05%
ACRV Acrivon Therapeutics, Inc.
9.39
-10.91%
ADAP Adaptimmune Therapeutics plc
0.9767
+8.72%
CHRS Coherus BioSciences, Inc.
2.0700
+3.50%
CMRX Chimerix, Inc.
0.8844
-5.14%